Fenfluramine cut convulsive seizures 62.3% more than placebo, but its REMS burden and 3x price premium over cannabidiol define the real contest.

Dravet syndrome's US market rests on three FDA-approved, syndrome-specific agents layered atop a generic valproate and clobazam backbone. Cannabidiol (Epidiolex, Jazz Pharmaceuticals) was approved in June 2018 as the first cannabis-derived FDA drug. Fenfluramine (Fintepla, UCB) followed in June 2020 with a REMS cardiac-monitoring requirement. Stiripentol (Diacomit, Biocodex) was approved in August 2018 for adjunctive use with valproate and clobazam.

In its pivotal Study 1, fenfluramine 0.7 mg/kg/day produced a 62.3% greater reduction in monthly convulsive seizure frequency than placebo, the strongest published result in the class, but carries a REMS echocardiography burden and a weight-based list price averaging near $96,000 per year. Cannabidiol's GWPCARE1 trial showed a 38.9% median seizure reduction versus 13.3% on placebo at a lower list price near $32,000 per year, and no generic has yet entered the market.

Cost, not clinical superiority, is what decides step-edit position in this small population.

Five questions this report answers:

Q1 - How do cannabidiol, fenfluramine and stiripentol differentiate on efficacy, route and safety monitoring burden?

Q2 - How does the cost gap between fenfluramine and cannabidiol shape step-edit design in this class?

Q3 - Where does fenfluramine's efficacy advantage translate into share, and where does cost blunt it?

Q4 - Why is generic cannabidiol not expected in the US market until the late 2030s?

Q5 - What REMS cardiac-monitoring requirement does fenfluramine carry that the other two agents do not?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#DravetSyndrome #US #CompetitiveIntelligence #AXLRx #RareDisease

Live report page:  https://axlrx.ai/dravet-syndrome/competitive-intelligence/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-   hello@axlrx.ai

Web-   https://axlrx.ai/